| Pulmonary Arterial Hypertension |
1 |
1 |
| Hypertension |
0 |
0.88 |
| Artery |
0 |
0.75 |
| Heart Failure (HF) |
0 |
0.75 |
| Myocardial Infarction (MI) |
0 |
0.57 |
| Heart |
0 |
0.38 |
| Viagra |
0 |
0.3 |
| Meta-Analysis |
0 |
0.23 |
| Adverse Effects |
0 |
0.15 |
| Erectile Dysfunction |
0 |
0.15 |
| Hospital |
0 |
0.15 |
| Nitric Oxide |
0 |
0.15 |
| B-Type Natriuretic Peptide |
0 |
0.11 |
| In-Stent Restenosis |
0 |
0.11 |
| Patient Safety |
0 |
0.11 |
| Ablation |
0 |
0.07 |
| Animal Research |
0 |
0.07 |
| Biologic Therapy |
0 |
0.07 |
| Brain |
0 |
0.07 |
| Clinical Research |
0 |
0.07 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Hemodynamics |
0 |
0.07 |
| Illinois |
0 |
0.07 |
| Muscle |
0 |
0.07 |
| Nerve |
0 |
0.07 |
| Pathogenesis |
0 |
0.07 |
| Phosphodiesterase Inhibitor |
0 |
0.07 |
| Prognosis |
0 |
0.07 |
| Prostacyclin |
0 |
0.07 |
| Pulmonary Hypertension |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Sexual Dysfunction |
0 |
0.07 |
| Targeted Cancer Therapy |
0 |
0.07 |
| Texas |
0 |
0.07 |
| Thrombosis |
0 |
0.07 |
| Tissue |
0 |
0.07 |
| Trunk |
0 |
0.07 |
| Thromboembolism |
0 |
0.06 |